Global Health Governance from Below: Access to AIDS Medicines, International Human Rights Law, and Social Movements - Innovation in Global Health Governance - page 203

some headway in achieving this goal. However, as James orbinski (2007) suggests,
rights achieved must be defended and constant vigilance is required to maintain
hard-won gains. Ensuring that human rights influence political practices regarding
medicines and their underlying normative foundations requires consistent and
persistent advocacy toward an alternative normative framework for global health
governance.

Notes

1 Pharmaceutical Manufacturers' Association and Others v. The President of the Republic

of South Africa. case no. 4183/98, trans. Prov. Div.

2 Minister of Health and Another v. Treatment Action Campaign and Others (2002) 5 South

african law report 721 (South african constitutional court); Hazel Tau & Others v.
GlaxoSmithKline and Boehringer Ingelheim, competition commission of South africa,
2002. More generally, see Forman (2007).

3 AIDS Access Foundation et al. v. Bristol Myers-Squibb Company and Department of

Intellectual Property (2002), central Intellectual Property and International trade court,
black case no. tor Por 34/2544, red case no. 92/2545.

Reference

abbott, Frederick M. (2002). 'wto trIPS agreement and Its Implications for access to
Medicines in Developing countries.' Study Paper 2a for the commission on Intellectual
Property rights. commission on Intellectual Property rights. <www.iprcommission.org/
papers/pdfs/study_papers/sp2a_abbott_study.pdf> (September 2008).
baxi, Upendra (2002). The Future of Human Rights . (new York: oxford University Press).
benatar, Solomon r., abdallah Daar, and Peter a. Singer (2003). 'Global Health ethics: the
rationale for Mutual caring.' International Affairs, vol. 79, no. 1, pp. 107-138.
Carrozza, Paolo G. (2003). 'From Conquest to Constitutions: Retrieving a Latin American
tradition of the Idea of Human rights.' Human Rights Quarterly, vol. 25, no. 2,
pp. 281-313.
Caves, Richard E., Michael D. Whinston, Mark A. Hurwitz , et al. (1991). 'Patent expiration,
entry, and competition in the U.S. Pharmaceutical Industry.' Brookings Papers on
Economic Activity, vol. 1991, pp. 1-66.
commission on Intellectual Property rights, Innovation, and Public Health (2006). Public
Health: Innovation and Intellectual Property Rights. World Health Organization, Geneva.
<www.who.int/entity/intellectualproperty/documents/thereport/enPublicHealthreport.
pdf> (September 2008).
cooper, andrew F., John J. Kirton, and ted Schrecker (2007). 'toward Innovation in Global
Health Governance.' In a.F. cooper, J.J. Kirton, and t. Schrecker, eds., Governing Global
Health: Challenge, Response, Innovation, pp. 229-239 (aldershot: ashgate).
correa, carlos (2002). 'Public Health and Intellectual Property rights.' Global Public Policy,
vol. 2, no. 3, pp. 261-278.
crenshaw, Kimberle (2000). 'were the critics right about rights? reassessing the american
Debate about rights in the Post-reform era.' In M. Mamdani, ed., Beyond Rights Talk